Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) saw a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 1,100 shares, a drop of 15.4% from the February 28th total of 1,300 shares. Based on an average daily volume of 15,900 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the shares of the company are sold short.
Addex Therapeutics Stock Performance
NASDAQ:ADXN opened at $7.45 on Thursday. The stock has a 50-day simple moving average of $7.68 and a two-hundred day simple moving average of $8.52. Addex Therapeutics has a 52-week low of $6.67 and a 52-week high of $27.90. The firm has a market capitalization of $7.90 million, a PE ratio of -21.91 and a beta of 1.76.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Addex Therapeutics stock. Citadel Advisors LLC bought a new stake in shares of Addex Therapeutics Ltd (NASDAQ:ADXN – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 12,079 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 1.14% of Addex Therapeutics at the end of the most recent quarter. 16.14% of the stock is currently owned by institutional investors.
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Featured Stories
- Five stocks we like better than Addex Therapeutics
- How to Use Stock Screeners to Find Stocks
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- Bank Stocks – Best Bank Stocks to Invest In
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Roth IRA Calculator: Calculate Your Potential Returns
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
